Year-end Sale % OFF 
Abstract
Increasing approvals and rising budget impact of cancer treatments over the past few decades have raised the need for value-based contracting – arrangements between healthcare payers and biopharmaceutical companies that allow coverage of new medicines while accommodating uncertainties around their performance and financial impact. The objective of this study was to identify and analyze publicly available value-based contracts (VBCs) for oncology drugs.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
